Abstract |
A combination of imipenem (MK-0787), a new carbapenem antibiotic, plus cilastatin sodium (MK-0791), a dehydropeptidase inhibitor ( MK-0787/ MK-0791 = 1:1) was studied in the field of obstetrics and gynecology and the following results were obtained. Absorption and penetration into genital organ tissues were good. Following a 0.5 g/0.5 g intravenous drip infusion, the maximum plasma concentration in uterine arterial blood was 20.8 micrograms/ml, and the maximum concentrations of the drug in tissues were 9.9 approximately 16.8 micrograms/g, and these levels of MK-0787 exceeded the MIC values against main causative organisms. Rates of elimination of the drug from the tissue and from the plasma were similar. Against gynecological and obstetrical infections, a dose of 0.5 g/0.5 g twice daily for an average duration of 6.3 days produced a clinical efficacy ratio of 94.4% (17/18) and a bacteriological effects rating of 76.9% (10/13). As side effects, one patient showed an eruption and another had an elevated GOT and GPT. Based on the above results, MK-0787/ MK-0791 appears to be effective against gynecological and obstetrical infections.
|
Authors | N Cho, K Fukunaga, K Kunii |
Journal | The Japanese journal of antibiotics
(Jpn J Antibiot)
Vol. 39
Issue 5
Pg. 1359-71
(May 1986)
ISSN: 0368-2781 [Print] Japan |
PMID | 3463782
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Cyclopropanes
- Drug Combinations
- Thienamycins
- Cilastatin
- Imipenem
|
Topics |
- Adult
- Aged
- Bacterial Infections
(drug therapy)
- Cilastatin
- Cyclopropanes
(administration & dosage, metabolism)
- Drug Combinations
- Female
- Genital Diseases, Female
(drug therapy)
- Genitalia, Female
(metabolism)
- Humans
- Imipenem
- Kinetics
- Middle Aged
- Postoperative Complications
(drug therapy)
- Pregnancy
- Pregnancy Complications, Infectious
(drug therapy)
- Thienamycins
(administration & dosage, metabolism)
|